Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BioNTech SE    BNTX

BIONTECH SE

(BNTX)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/13/2020 01/14/2020 01/15/2020 01/16/2020 01/17/2020 Date
37.83(c) 34.53(c) 34.55(c) 32.25(c) 33.18(c) Last
459 593 266 343 361 022 692 185 615 260 Volume
-4.66% -8.72% +0.06% -6.66% +2.88% Change
More quotes
Financials (EUR)
Sales 2019 109 M
EBIT 2019 -164 M
Net income 2019 -154 M
Finance 2019 554 M
Yield 2019 -
Sales 2020 96,5 M
EBIT 2020 -205 M
Net income 2020 -188 M
Finance 2020 214 M
Yield 2020 -
P/E ratio 2019 -42,2x
P/E ratio 2020 -35,3x
EV / Sales2019 59,4x
EV / Sales2020 70,7x
Capitalization 7 037 M
More Financials
Company
More about the company
Latest news on BIONTECH SE
01/16NEON THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Even..
AQ
01/16BioNTech to acquire Neon to strengthen global leadership position in T cell t..
GL
01/15BIONTECH : J.P. Morgan Presentation
PU
01/13BioNTech Appoints Ryan Richardson as Chief Strategy Officer to Support its Co..
GL
01/02BioNTech Announces Publication of Preclinical Data for First-in-Kind CAR-T Ce..
GL
2019BioNTech to Present at the 38th Annual J.P. Morgan Healthcare Conference
GL
2019European Investment Bank provides funding of €50 million to BioNTech as part ..
GL
2019BioNTech SE Provides Update on Corporate Progress and Third Quarter 2019 Fina..
GL
2019BioNTech to Report Third Quarter 2019 Financial Results and Operational Progr..
GL
2019Yacht maker Ferretti's cancellation caps dismal European IPO season
RE
2019BIOH : BioNTech Announces Pricing of Initial Public Offering
BU
More news
News in other languages on BIONTECH SE
01/16Biotechfirma BioNTech kauft US-Krebsspezialisten
01/14Deutsche Start-ups erleben Boom - und sind vom Ausland abhängig
2019BIONTECH IM FOKUS : Spekulation auf Revolutionierung der Medizin
2019BioNTech-Mitbegründer rechnet mit früherer Krebs-Diagnostik
2019IPO : Biotech-Unternehmen Centogene holt sich an der Nasdaq Geld für Wachstum
More news
Sector news : Bio Therapeutic Drugs
01/14Freeport Rules Out Deals in Near Term -- WSJ
DJ
01/13Freeport-McMoran Isn't Looking for Strategic Deals in Coming Years, CEO Says
DJ
01/13Novartis to speed access to $10 billion heart drug via NHS deal
RE
01/13Drugmakers Test New Ways to Pay for Six-Figure Treatments
DJ
01/08In a vigorous defense, Carlos Ghosn claims he has done nothing wrong
More sector news : Bio Therapeutic Drugs
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 19,74  €
Last Close Price 29,92  €
Spread / Highest target -25,3%
Spread / Average Target -34,0%
Spread / Lowest Target -39,5%
EPS Revisions
Sector and Competitors
1st jan.Capitalization (M$)
BIONTECH SE-2.07%7 802
GILEAD SCIENCES-3.08%79 679
VERTEX PHARMACEUTICALS7.71%60 644
REGENERON PHARMACEUTICALS2.79%42 192
WUXI APPTEC CO., LTD.6.39%23 468
GENMAB2.50%14 657